Abstract
BackgroundImmune Checkpoint Blockade (ICB) with anti- programmed cell death protein (PD)-1 and anti-cytotoxic T lymphocyte associated protein (CTLA)-4 have had immense success in cancer treatment. However, primary and acquired resistance...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have